ReviewVeterinary research2022
How Streptococcus suis escapes antibiotic treatments.
Review in Veterinary research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 102 citations in OpenAlex.
- A descriptive analysis of Streptococcus suis-associated disease in Irish pigs from 2010 to 2024: serotypes, pathology, and antimicrobial resistance.Irish veterinary journal · 2026Article
- Clinically relevant genomic and phenotypic differences in virulence, antimicrobial resistance, and biofilm-associated tolerance between Streptococcus suis lineages ST1 and ST123.Veterinary research · 2026Article
- Evidence of transfer of antimicrobial resistance genes from the porcine pathogenOne health (Amsterdam, Netherlands) · 2026Article
- Combined Supplementation of Live Yeast and Yeast Postbiotics Enhances Antioxidant Capacity and Intestinal Health in Weaned Piglets.Antioxidants (Basel, Switzerland) · 2026Article
- Ribosomal protein RPSA is a promising target for the prevention of Streptococcus suis serotype 2.Applied microbiology and biotechnology · 2026Article
- Penicillin-nonsusceptible Streptococcus suis infections in humans: clinical characteristics and antimicrobial synergy testing.BMC infectious diseases · 2026Article
- A conserved glycan motif induces broadly reactive functional antibodies against the zoonotic pathogenScience advances · 2026Article
- Bayesian network models to assess antimicrobial resistance patterns of Streptococcus suis isolated from swine production systems in the United States between 2014-2021.PLoS computational biology · 2026Article
- Integrated analysis of GWAS and molQTLs reveals cell-specific genetic variants in the porcine immune system.Communications biology · 2026Article
- In Vitro Synergistic Effects of Antibiotic Combinations Against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Cathelicidin CATH-2 suppresses the NF-κB/ROS/NLRP3 signaling pathway via regulating mTOR-dependent autophagy during Streptococcus suis infection.Veterinary research · 2026Article
- [Advances in the Regulation of Protein Phosphorylation in Streptococcal Cell Wall Synthesis].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Review
- Antibacterial Activity of Bacteriophage Lytic Enzyme Ply900.Veterinary sciences · 2026Article
- Streptococcus suis infection as an emerging zoonotic threat in Brazil: a One Health-based review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Review
- Comparative evaluation of trimethoprim-sulfonamide ratios and synergistic interactions against porcine respiratory pathogens.Frontiers in veterinary science · 2026Article
- Serovar-Dependent Gene Regulation and Antimicrobial Tolerance inAntibiotics (Basel, Switzerland) · 2025Article
- Streptococcus suis avian expansion suggests shared antibiotic use drives host jumps.BMC biology · 2025Article
- Article
- Review
- Recombinant Extracellular Factor Protein ofVaccines · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Streptococcus suis is a zoonotic agent that causes sepsis and meningitis in pigs and humans. S. suis infections are responsible for large economic losses in pig production. The lack of effective vaccines to prevent the disease has promoted the extensive use of antibiotics worldwide. This has been followed by the emergence of resistance against different classes of antibiotics. The rates of resistance to tetracyclines, lincosamides, and macrolides are extremely high, and resistance has spread worldwide. The genetic origin of S. suis resistance is multiple and includes the production of target-modifying and antibiotic-inactivating enzymes and mutations in antibiotic targets. S. suis genomes contain traits of horizontal gene transfer. Many mobile genetic elements carry a variety of genes that confer resistance to antibiotics as well as genes for autonomous DNA transfer and, thus, S. suis can rapidly acquire multiresistance. In addition, S. suis forms microcolonies on host tissues, which are associations of microorganisms that generate tolerance to antibiotics through a variety of mechanisms and favor the exchange of genetic material. Thus, alternatives to currently used antibiotics are highly demanded. A deep understanding of the mechanisms by which S. suis becomes resistant or tolerant to antibiotics may help to develop novel molecules or combinations of antimicrobials to fight these infections. Meanwhile, phage therapy and vaccination are promising alternative strategies, which could alleviate disease pressure and, thereby, antibiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.